Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD)

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany (2022) Mohr P, Scherrer E, Assaf C, Bender M, Berking C, Chandwani S, Eigentler T, et al. Journal article Non-invasive imaging as the cornerstone of cardiovascular precision medicine (2022) Achenbach S, Fuchs F, Goncalves A, Kaiser-Albers C, Ali ZA, Bengel FM, Dimmeler S, et al. Journal article Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review (2022) Huang M, Haiderali A, Fox GE, Frederickson A, Cortes J, Fasching P, O'Shaughnessy J Journal article, Review article Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies (2022) Gorski M, Rasheed H, Teumer A, Thomas LF, Graham SE, Sveinbjornsson G, Winkler TW, et al. Journal article KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC (2021) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kummel S, Bergh J, et al. Conference contribution Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, et al. Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, et al. Journal article Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline (2021) Gorski M, Jung B, Li Y, Matias-Garcia PR, Wuttke M, Coassin S, Thio CH, et al. Journal article Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis (2020) Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey SD, Briggs A, et al. Journal article, Review article KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC) (2020) Dent R, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution